Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Year Ahead: Bisphosphonate Class Faces Generic Competition – Fosamax Goes Off Patent

Executive Summary

Merck's Fosamax (alendronate) will be one of the key branded drugs facing generic competition in 2008, and the availability of a low-cost version of the market-leading osteoporosis drug could have a wide-reaching impact on the bisphosphonate class and beyond

You may also be interested in...



Merck Commercial Pilot Set To Fly Nationwide

Merck is rolling out a new commercial model, including a realigned sales organization, nationwide following a successful pilot program, Global Human Health President Kenneth Frazier said

Merck Commercial Pilot Set To Fly Nationwide

Merck is rolling out a new commercial model, including a realigned sales organization, nationwide following a successful pilot program, Global Human Health President Kenneth Frazier said

Drug Safety Concerns Help Depress U.S. Sales Forecasts From IMS Health

Drug safety concerns contributed to IMS Health's decision to lower its forecast for the compound annual pharmaceutical sales growth rate over the next several years

Related Content

UsernamePublicRestriction

Register

PS049272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel